Equities
Health CareMedical Equipment and Services
  • Price (USD)119.43
  • Today's Change0.10 / 0.08%
  • Shares traded1.30m
  • 1 Year change-13.53%
  • Beta1.0408
Data delayed at least 15 minutes, as of Apr 19 2024 21:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Zimmer Biomet Holdings, Inc. is a global medical technology company. Its segments include Americas, EMEA, and Asia Pacific. The Company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic (CMFT) products; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its other product category primarily includes its robotic, surgical and bone cement products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee, and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System, and G7 Acetabular System. Its S.E.T. product category includes sports medicine, biologics, foot and others.

  • Revenue in USD (TTM)7.39bn
  • Net income in USD1.02bn
  • Incorporated2001
  • Employees18.00k
  • Location
    Zimmer Biomet Holdings Inc345 E Main StWARSAW 46580-2746United StatesUSA
  • Phone+1 (574) 267-6131
  • Fax+1 (302) 636-5454
  • Websitehttps://www.zimmerbiomet.com/en
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ZBH:NYQ since
announced
Transaction
value
Video Interventionelle Medicale Scientifique SASAnnounced22 Feb 202422 Feb 2024Announced-6.95%--
Ossis LtdAnnounced01 May 202301 May 2023Announced-13.73%--
Data delayed at least 15 minutes, as of Apr 19 2024 21:10 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shockwave Medical Inc730.23m147.28m12.28bn1.47k84.8818.1277.9316.823.863.8619.1318.080.661.047.86497,431.9013.3110.2914.4011.3986.9484.6920.1715.1410.7319.700.52260.0049.11126.45-31.81--72.88--
Hologic Inc3.97bn515.10m17.63bn6.99k35.703.7820.964.442.102.1016.1319.840.4472.705.90567,854.105.8011.406.4813.3855.4460.2912.9820.953.18--0.35650.00-17.124.61-64.98--7.30--
Cooper Companies Inc3.67bn290.80m17.97bn15.00k91.362.3327.004.900.98960.98967.3638.730.31081.775.95244,420.002.4710.062.6811.3466.0965.547.9329.001.084.920.26490.34698.617.24-23.74-3.6615.1831.95
Steris PLC5.41bn566.84m19.84bn17.00k35.413.0917.393.675.675.6754.1864.930.48643.946.05318,081.405.113.995.544.3743.6043.4110.507.901.496.420.339949.058.1313.61-56.12-17.0216.958.74
Baxter International Inc14.81bn-76.00m20.20bn60.00k--2.4016.911.36-0.15085.2229.2316.550.52383.435.48246,883.30-0.2440.1942-0.30540.233335.8938.20-0.46580.36741.043.280.61971,398.942.125.9497.15--0.9829.71
Align Technology, Inc.3.86bn445.05m22.68bn21.61k51.826.2338.605.875.815.8150.4348.360.6423.644.38178,725.607.4016.3411.0724.1470.0871.7211.5223.161.04--0.000.003.4214.4523.092.15-4.46--
Zimmer Biomet Holdings Inc7.39bn1.02bn24.52bn18.00k24.411.9712.403.324.894.8935.2660.700.34750.91955.24410,794.404.822.215.492.5271.8271.2513.867.280.77847.320.31638.906.55-1.40252.86--9.440.00
Resmed Inc4.50bn890.39m26.12bn10.14k29.425.8324.395.806.046.0430.5330.470.66332.106.17444,189.1013.1113.5914.7415.8955.1156.9819.7719.221.8919.640.214936.6618.0212.5315.1514.6313.404.68
West Pharmaceutical Services Inc.2.95bn593.40m27.62bn10.60k47.879.6338.749.367.887.8839.1939.200.79234.295.79278,283.0015.4615.6118.4118.6538.2838.0619.5218.472.24--0.06710.692.1811.432.2823.7628.166.20
Data as of Apr 19 2024. Currency figures normalised to Zimmer Biomet Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

43.10%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 202322.98m11.20%
BlackRock Fund Advisorsas of 31 Dec 202311.77m5.74%
Dodge & Coxas of 31 Dec 202311.47m5.60%
SSgA Funds Management, Inc.as of 31 Dec 20239.31m4.54%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 20239.14m4.46%
American Century Investment Management, Inc.as of 31 Dec 20235.93m2.89%
PRIMECAP Management Co.as of 31 Dec 20235.09m2.48%
Invesco Advisers, Inc.as of 31 Dec 20234.84m2.36%
Geode Capital Management LLCas of 31 Dec 20234.60m2.24%
JPMorgan Investment Management, Inc.as of 31 Dec 20233.26m1.59%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.